January « 2023 « Science and Enterprise

Psychedelic Drug Shown to Relieve PTSD Brain Signals

By Alan, on January 20th, 2023%

A small clinical trial shows psychotherapy with the psychedelic drug MDMA generates brain signals that help relieve symptoms in people with post-traumatic stress disorder. . . . → Read More: Psychedelic Drug Shown to Relieve PTSD Brain Signals

Real-World Data Shown to Match Eye Disease Trial Results

By Alan, on January 19th, 2023%

Research findings show data in patients’ electronic health records can be collected and analyzed to replicate results from late-stage clinical trials of an eye disease biologic drug. . . . → Read More: Real-World Data Shown to Match Eye Disease Trial Results

QuickDNA Tests Meet International Lab Industry Standards

By Alan, on January 19th, 2023%

For laboratory tests with enormous consequences to their subjects, it’s vital that the labs conducting the tests meet exacting standards for quality and reliability. . . . → Read More: QuickDNA Tests Meet International Lab Industry Standards

Biotech, Academic Lab Partner on Microbiome-Safe Products

By Alan, on January 18th, 2023%

A biotechnology company creating products for gut health and a university immunology lab are evaluating cleaning products for potential damage to human protective tissues. . . . → Read More: Biotech, Academic Lab Partner on Microbiome-Safe Products

Trial to Assess At-Home Asthma Lung Function Tests

By Alan, on January 17th, 2023%

A clinical trial is set to begin that compares monitoring of lung functions in people with asthma using portable ultrasound and mobile app at home to conventional tests in a clinic. . . . → Read More: Trial to Assess At-Home Asthma Lung Function Tests

Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

By Alan, on January 16th, 2023%

A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine. . . . → Read More: Nasal Spray Vaccine Shown to Stop Gonorrhea Infections

Infographic – 2022 Biotech Venture Funding Weakens

By Alan, on January 14th, 2023%

Chart: Venture investments total by year for biotech and pharma companies

Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening. . . . → Read More: Infographic – 2022 Biotech Venture Funding Weakens

Environmental Biomarker Start-Up Gains $16M in Early Funds

By Alan, on January 13th, 2023%

A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds. . . . → Read More: Environmental Biomarker Start-Up Gains $16M in Early Funds

CEPI Assessing Advanced RNA Nanoparticle Vaccine

By Alan, on January 12th, 2023%

An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics. . . . → Read More: CEPI Assessing Advanced RNA Nanoparticle Vaccine

Audio Digital Biomarkers Start-Up Raises $3.7M in Seed Funds

By Alan, on January 11th, 2023%

A new company developing techniques to analyze internal physiological sounds captured by stethoscopes as health indicators is raising $3.7 million in seed funds. . . . → Read More: Audio Digital Biomarkers Start-Up Raises $3.7M in Seed Funds

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise